Ligand Pharmaceuticals IncLGND

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$299.04
Market cap
$6.0B
P/E
30.2x
Revenue (TTM)
$290.5M
Net income
$197.2M
Dividend yield
—
1-year total return
79.3%
Net margin
67.9%
Revenue growth
54.9%
Debt / equity
1.16x

What Ligand Pharmaceuticals Inc does.

We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure. Capital deployment and technology licensing are the primary drivers of our long-term growth.

We partner capital through a range of transaction structures—including royalty purchases, development-stage financing arrangements, and acquisitions of companies or assets with embedded royalty rights—designed to create cash flowing royalties and produce attractive risk-adjusted returns. Our goal is to provide investors with exposure to biopharmaceutical innovation through a diversified portfolio of royalty interests while mitigating the binary risk and capital intensity traditionally associated with drug development.

In addition to our royalty investment activities, we operate two infrastructure-light, royalty-generating platform technologies, Captisol ® and NITRICIL ® . These technologies exemplify our platform technology investment criteria: infrastructure-light, scalable intellectual property with existing royalty streams and the potential to generate incremental royalties through partner-driven development and commercialization.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$163.6M$241.5M$196.2M$131.3M$167.1M$268.1M
Net income-$3.0M$57.1M-$33.4M$52.2M-$4.0M$124.5M
Free cash flow$50.1M$70.0M$119.9M$46.1M$95.2M$48.9M

More on LGND.

Figures from Ligand Pharmaceuticals Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.